Is a risk evaluation and mitigation strategy (REMS) still needed for clozapine? That's what a joint meeting of two FDA advisory committees will discuss on Tuesday. Risk management requirements for the ...

Clozapine is widely considered the most effective treatment for patients with severe schizophrenia. But across the U.S., people were repeatedly denied access to it because of a federal monitoring ...

The risk for moderate neutropenia associated with clozapine therapy is low in patients with treatment-resistant schizophrenia, and the risk for severe neutropenia is minimal, new research showed. None ...

An inter-departmental research team has conducted an analytic real-world cohort study on the association of clozapine, a highly efficacious antipsychotic drug, with the incidence of blood cancer.